Provectus’ PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncolog...
April 21 2014 - 6:00AM
Business Wire
Presentation Scheduled for Wednesday, May 7,
2014, in Vilnius Lithuania
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT)
(http://www.pvct.com), a development-stage oncology and dermatology
biopharmaceutical company, announced today that Dr. Sanjiv Agarwala
of St. Luke's University Health Network will present clinical data
on Provectus’ PV-10 preparation for the treatment of melanoma at
the 10th European Association of Dermato-Oncology (EADO) Congress
in Vilnius, Lithuania. The Congress runs from May 7-10, 2014, and
Dr. Agarwala’s presentation is scheduled for the first day of the
Congress, Wednesday, May 7.
Dr. Craig Dees, PhD, CEO of Provectus, said, "Provectus is happy
to see our colleague Dr. Agarwala sharing what he and his team at
St. Luke’s have learned about PV-10 in the treatment of melanoma
with the members of EADO at this year’s Congress.”
PV-10, a 10% solution of Rose Bengal that is currently being
examined as a novel cancer therapeutic, is designed to selectively
target and destroy cancer cells without harming surrounding healthy
tissue, minimizing potential for systemic side effects.
About the European Association of Dermato-Oncology
The European Association of Dermato-Oncology is an independent
non-profit organization dedicated to promote, coordinate and
improve clinical and laboratory research activities in the field of
skin cancer including primary and secondary prevention, early
detection, clinical diagnosis and clinical and experimental
research. EADO has a European and international membership of
dermatologists, oncologists and clinical as well as basic research
scientists interested in the field of Dermato-Oncology and offers
coordination and support of projects of the respective national
skin cancer groups. For additional information about EADO please
visit the website at http://www.eado.org/.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. Its novel oncology drug PV-10 is
designed to selectively target and destroy cancer cells without
harming surrounding healthy tissue, significantly reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. Its dermatological drug PH-10
also targets abnormal or diseased cells, with the current focus on
psoriasis and atopic dermatitis. Provectus has recently completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and
of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the
Company's website at www.pvct.com or contact Porter, LeVay &
Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements
contained herein are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
reflected in the forward-looking statements. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which reflect management's analysis only as of the date hereof. The
company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date thereof.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO, COO,
866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
212-564-4700DM, SVP – Investor RelationsorBill Gordon,
212-724-6312Media Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
